Cited by 562Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Open access

Elman, Michael J., Ayala, Allison, Bressler, Neil M., Browning, David, Flaxel, Christina J., Glassman, Adam R., Jampol, Lee M., Stone, Thomas W.·2015·Ophthalmology

DOI 10.1016/j.ophtha.2014.08.047PMC PMC4520307

Open this paper in CoChat — free account

Abstract

Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks) focal/grid laser treatment for diabetic macular edema (DME).Design Multicenter, randomized clinical trial.Participants Among participants from the trial with 3 years of follow-up who subsequently consented to a 2-year extension and survived through 5 years, 124 (97%) and 111 (92%) completed the 5-year visit in the prompt and deferred groups, respectively.Methods Random assignment to ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and prompt or deferred (≥24 weeks) focal/grid laser treatment.Main outcome measures Best-corrected visual acuity at the 5-year visit.Results The mean change in visual acuity letter score from baseline to the 5-year visit was +7.2 letters in the prompt laser group compared with +9.8 letters in the deferred laser group (mean difference, -2.6 letters; 95% confidence interval, -5.5 to +0.4 letters; P = 0.09). At the 5-year visit in the prompt versus deferred laser groups, there was vision loss of ≥10 letters in 9% versus 8%, an improvement of ≥10 letters in 46% versus 58%, and an improvement of ≥15 letters in 27% versus 38% of participants, respectively. From baseline to 5 years, 56% of participants in the deferred group did not receive laser. The median number of injections was 13 versus 17 in the prompt and deferral groups, including 54% and 45% receiving no injections during year 4 and 62% and 52% receiving no injections during year 5, respectively.Conclusions Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2014.08.047

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,431
Self-citation
The RESTORE Study
Mitchell, P., Bandello, F. M., Schmidt-Erfurth, U. M., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,344
Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 572
Self-citation
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
Elman, M. J., Qin, H., Aiello, L. P., Beck, R. W., Bressler, N. M., Ferris, F. L., Glassman, A. R., Maturi, R. K., & Melia, M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.022 · Cited by 322
Self-citation
Mixed models for longitudinal data
Cecílio‐Fernandes, D., Tio, R. A., & Jaarsma, D. A. D. C. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 118
Reproducibility of Spectral-Domain Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Time-Domain Metrics in Diabetic Macular Edema
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 105
Self-citation
Inference for the Marginal Model
(2009) · Springer series in statistics · doi:10.1007/978-1-4419-0300-6_6 · Cited by 6

Show all 10 references

Sorted by citations

Items 101–200 of 560

Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE
Pieramici, D. J., Wang, P.-W., Ding, B., & Gune, S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.02.007 · Cited by 57
Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes
Klaassen, I., de Vries, E. W., Vogels, I. M. C., van Kampen, A. H. C., Bosscha, M. I., STEEL, D. H., Noorden, C. J. F. V., Oberstein, S. Y. L., & Schlingemann, R. O. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187304 · Cited by 57
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies
Mitchell, P., McAllister, I. L., Larsen, M., Staurenghi, G., Korobelnik, J., Boyer, D. S., Diana, V., Brown, D. M., Katz, T. A., Berliner, A. J., et al. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.02.011 · Cited by 56
Intravitreal Therapy for Diabetic Macular Edema: An Update
Furino, C., Boscia, F., Reibaldi, M., & Alessio, G. (2021) · Journal of Ophthalmology · doi:10.1155/2021/6654168 · Cited by 61
Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study
Sadiq, M. A., Soliman, M. K., Sarwar, S., Agarwal, A. K., Hanout, M., Demirel, S., Rentiya, Z., Khan, W., Diana, V., Nguyen, Q. D., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.032 · Cited by 55
Five-Year Cost-Effectiveness Modeling of Primary Care-Based, Nonmydriatic Automated Retinal Image Analysis Screening Among Low-Income Patients With Diabetes
Fuller, S. D., Hu, J. Q., Liu, J. C., Gibson, E., Gregory, M. H., Kuo, J., & Rajagopal, R. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820967011 · Cited by 60
Telemedicine in diabetic retinopathy: Current status and future directions
Das, T., Raman, R., Ramasamy, K., & Rani, P. K. (2015) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.154391 · Cited by 54
Prediction of response to anti‐vascular endothelial growth factor treatment in diabetic macular oedema using an optical coherence tomography‐based machine learning method
Cao, J., You, K., Jin, K., Lou, L., Wang, Y., Chen, M., Pan, X., Shao, J., Su, Z., Wu, J., et al. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14514 · Cited by 53
A Review of Ranibizumab for the Treatment of Diabetic Retinopathy
Stewart, M. W. (2017) · Ophthalmology and Therapy · doi:10.1007/s40123-017-0083-9 · Cited by 57
Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials
Wykoff, C. C., Elman, M. J., Regillo, C. D., Ding, B., Lu, N., & Stoilov, I. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.004 · Cited by 50
Self-citation
Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials
Parrish, R. K., II, Campochiaro, P. A., Pearson, P. A., Green, K., Traverso, C. E., & FAME Study Group (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20160419-05 · Cited by 51
Indocyanine green angiography for identifying telangiectatic capillaries in diabetic macular oedema
Farias, D. C., Serrano, R. M., Gancharov, J. B., Cuadras, U. D. D., Sahel, J., Wiechers, F. G., Dupas, B., & Pâques, M. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-314355 · Cited by 51
Intravitreal Injection of Ranibizumab and CTGF shRNA Improves Retinal Gene Expression and Microvessel Ultrastructure in a Rodent Model of Diabetes
Hu, B., Zhang, Y., Zeng, Q., Han, Q., Zhang, L., Liu, M., & Li, X. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15011606 · Cited by 51
Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Real-Life Data from a Prospective Study and Predictive Factors for Visual Outcome
Chatziralli, I., THEODOSSIADIS, P. G., Parikakis, E., Dimitriou, E., Xirou, T., THEODOSSIADIS, G. P., & Kabanarou, S. A. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0332-x · Cited by 50
Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities
Stewart, M. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10010021 · Cited by 49
Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants
on behalf of the FAME study group, Yang, Y. C., Bailey, C., Holz, F. G., Eter, N., Weber, M., Baker, C. W., Kiss, S., Menchini, U., Ruiz‐Moreno, J. M., et al. (2015) · Eye · doi:10.1038/eye.2015.98 · Cited by 49
Revolution to a New Standard Treatment of Diabetic Macular Edema
Jampol, L. M., Bressler, N. M., & Glassman, A. R. (2014) · JAMA · doi:10.1001/jama.2014.2536 · Cited by 48
Self-citation
PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA
Shah, S. U., Harless, A. M., Bleau, L., & Maturi, R. K. (2016) · Retina · doi:10.1097/iae.0000000000001038 · Cited by 48
Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
Lai, T. Y. Y., & Fong, A. H. C. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s36811 · Cited by 50
Nationale Versorgungsleitlinie (NVL) Diabetische Retinopathie
Ziemssen, F., Lemmen, K. D., Bertram, B., Hammes, H., & Agostini, H. T. (2016) · Der Ophthalmologe · doi:10.1007/s00347-016-0315-8 · Cited by 48
COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB
Bavinger, J. C., Yu, Y., & VanderBeek, B. L. (2018) · Retina · doi:10.1097/iae.0000000000002351 · Cited by 46
Postoperative Complications of Pars Plana Vitrectomy for Diabetic Retinal Disease
Yau, G. L., Silva, P. S., Arrigg, P. G., & Sun, J. K. (2017) · Seminars in Ophthalmology · doi:10.1080/08820538.2017.1353832 · Cited by 45
Laser-Based Strategies to Treat Diabetic Macular Edema: History and New Promising Therapies
Park, Y. G., Kim, E. Y., & Roh, Y. (2014) · Journal of Ophthalmology · doi:10.1155/2014/769213 · Cited by 44
Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network
Krick, T. W., & Bressler, N. M. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000472 · Cited by 44
Self-citation
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
Best, A., Fajnkuchen, F., Nghiem‐Buffet, S., Grenet, T., Quentel, G., Delahaye-Mazza, C., Cohen, S. Y., & Giocanti‐Auregan, A. (2018) · Journal of Ophthalmology · doi:10.1155/2018/4610129 · Cited by 44
Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease
Gale, R. P., Scanlon, P. H., Evans, M., Ghanchi, F. D., Yang, Y. C., Silvestri, G., Freeman, M., Maisey, A., & Napier, J. (2017) · Eye · doi:10.1038/eye.2017.53 · Cited by 42
Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial
Kanar, H. S., Arsan, A. K., Altun, A., Akı, S. F., & Hacısalihoğlu, A. (2019) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_350_19 · Cited by 42
Correlation between markers of renal function and sight-threatening diabetic retinopathy in type 2 diabetes: a longitudinal study in an Indian clinic population
Rajalakshmi, R., Rani, C. S. S., Venkatesan, U., Ranjit Unnikrishnan, I., Anjana, R. M., Rani, S. J., UmaSankari, G., Sivaprasad, S., Raman, R., & Mohan, V. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001325 · Cited by 45
Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy
Oshitari, T. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010439 · Cited by 45
Retinopathy
Altomare, F., Kherani, A., & Lovshin, J. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.027 · Cited by 45
One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema
Li, F., Zhang, L., Wang, Y., Xu, W., Jiao, W., Ma, A., & Zhao, B. (2017) · Current Eye Research · doi:10.1080/02713683.2017.1379542 · Cited by 41
Evolving strategies in the management of diabetic macular edema: clinical trials and current management
Thomas, B. J., Shienbaum, G., Boyer, D. S., & Flynn, H. W. (2013) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.11.012 · Cited by 40
INTRAOPERATIVE OPTICAL COHERENCE TOMOGRAPHY DURING VITREORETINAL SURGERY FOR DENSE VITREOUS HEMORRHAGE IN THE PIONEER STUDY
Ehlers, J. P., Griffith, J. F., & Srivastava, S. K. (2015) · Retina · doi:10.1097/iae.0000000000000660 · Cited by 40
Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation
Hirano, T., Toriyama, Y., Iesato, Y., Imai, A., Hirabayashi, K., Nagaoka, T., Takamura, Y., Sugimoto, M., & Murata, T. (2016) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-016-0483-8 · Cited by 42
Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema
Yoshida, S., Murakami, T., Nozaki, M., Suzuma, K., Baba, T., Hirano, T., Sawada, O., Sugimoto, M., Takamura, Y., & Tsuiki, E. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04936-w · Cited by 40
Strategy for the Management of Diabetic Macular Edema: The European Vitreo-Retinal Society Macular Edema Study
Adelman, R. A., Parnes, A. J., Michalewska, Z., Parolini, B., Boscher, C., & Ducournau, D. H. (2015) · BioMed Research International · doi:10.1155/2015/352487 · Cited by 41
Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study
Wykoff, C. C., Ou, W. C., Khurana, R. N., Brown, D. M., Clark, W. L., & Boyer, D. S. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-310941 · Cited by 39
Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis
Bande, M. F., Mansilla, R., Pata, M. P., Fernandez, M. B., Blanco‐Teijeiro, M. J., Piñeiro, A., & Gómez‐Ulla, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-18412-9 · Cited by 39
Update on Screening for Sight-Threatening Diabetic Retinopathy
Scanlon, P. H. (2019) · Ophthalmic Research · doi:10.1159/000499539 · Cited by 40
Perspectives of diabetic retinopathy—challenges and opportunities
Sivaprasad, S., Sen, S., & Cunha-Vaz, J. G. (2022) · Eye · doi:10.1038/s41433-022-02335-5 · Cited by 41
Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis
Reynolds, A., Álvarez, Y., Sasore, T., Waghorne, N., Butler, C. T., Kilty, C., Smith, A. J., McVicar, C., Wong, V. H. Y., Galvin, O., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710665 · Cited by 40
Therapeutic Options in Refractory Diabetic Macular Oedema
Shah, S. U., & Maturi, R. K. (2017) · Drugs · doi:10.1007/s40265-017-0704-6 · Cited by 38
Intravitreal dexamethasone implants for diabetic macular edema
Ríos, A., la Fuente-Rodríguez, P. R.-D., Bonaque‐González, S., López-Gálvez, M., López, V. L., & Romero‐Aroca, P. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.01.14 · Cited by 38
Emerging Insights and Interventions for Diabetic Retinopathy
Honasoge, A., Nudleman, E., Smith, M. E., & Rajagopal, R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1218-2 · Cited by 38
Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)
Dhoot, D. S., Pieramici, D. J., Nasir, M. A., CASTELLARIN, A. A., Couvillion, S., See, R. F., Steinle, N. C., Bennett, M., Rabena, M., & Avery, R. L. (2015) · Eye · doi:10.1038/eye.2014.338 · Cited by 37
Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies
Korobelnik, J., Lu, C., Katz, T. A., Dhoot, D. S., Loewenstein, A., Arnold, J. P., & Staurenghi, G. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.03.015 · Cited by 37
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
Aken, E. V., Favreau, M., Ramboer, E., Denhaerynck, K., MacDonald, K., Abraham, I. L., & Brié, H. (2020) · Clinical ophthalmology · doi:10.2147/opth.s281501 · Cited by 37
Pediatric Diabetic Retinopathy: Updates in Prevalence, Risk Factors, Screening, and Management
Lin, T., Gubitosi‐Klug, R., Channa, R., & Wolf, R. M. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01436-x · Cited by 38
Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies
Cheema, A. A., & Cheema, H. R. (2024) · Cureus · doi:10.7759/cureus.52676 · Cited by 36
Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment
Diana, V., Nguyen, Q. D., Vitti, R., Berliner, A. J., Gibson, A., Saroj, N., Soo, Y., & Boyer, D. S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.11.008 · Cited by 36
Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network
Baker, C. W., Jiang, Y., & Stone, T. W. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000262 · Cited by 36
Self-citation
Diabetic macular oedema: evidence‐based treatment recommendations for Asian countries
Cheung, C. M. G., Yoon, Y. H., Chen, L. J., Chen, S. J., George, T. M., Lai, T. Y. Y., Park, K. H., Tahija, S. G., Uy, H. S., & Wong, T. Y. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12999 · Cited by 35
Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial
Abouhussein, M. A., & Gomaa, A. (2020) · International Ophthalmology · doi:10.1007/s10792-019-01280-9 · Cited by 36
Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Мухаррамовна, Б. Г., Oshitari, T., Baba, T., & Yamamoto, S. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140508121927 · Cited by 36
Novel Therapies in Development for Diabetic Macular Edema
Agarwal, A. K., Afridi, R., Hassan, M., Sadiq, M. A., Sepah, Y. J., Diana, V., & Nguyen, Q. D. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0652-z · Cited by 35
Functional outcome of macular edema in different retinal disorders
Tomkins‐Netzer, O., Ismetova, F., Bar, A., Seguin‐Greenstein, S., Kramer, M., & Lightman, S. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.05.002 · Cited by 36
New Therapeutic Approaches in Diabetic Retinopathy
Vaziri, K., Schwartz, S. G., Relhan, N., Kishor, K. S., & Flynn, H. W. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.196 · Cited by 35
One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema
Schwarzer, P., Ebneter, A., Munk, M. R., Wolf, S., & Zinkernagel, M. S. (2019) · Ophthalmologica · doi:10.1159/000495623 · Cited by 35
Trends in the Care of Diabetic Macular Edema: Analysis of a National Cohort
VanderBeek, B. L., Shah, N., Parikh, P. C., & Ma, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149450 · Cited by 35
What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?
Agarwal, A. K., Sarwar, S., Sepah, Y. J., & Nguyen, Q. D. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000152 · Cited by 34
Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study
Wykoff, C. C., Le, R. T., Khurana, R. N., Brown, D. M., Ou, W. C., Wang, R. C., Clark, W. L., & Boyer, D. S. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.09.029 · Cited by 34
Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
Distéfano, L. N., García‐Arumí, J., Martínez-Castillo, V. J., & Boixadera, A. (2017) · Journal of Ophthalmology · doi:10.1155/2017/2407037 · Cited by 34
Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes
Sarohia, G. S., Nanji, K., Khan, M. D., Khalid, M. F., Rosenberg, D., Deonarain, D. M., Phillips, M., Thabane, L., Kaiser, P. K., Garg, S. J., et al. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.04.003 · Cited by 34
The Role of Plasma Kallikrein–Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches
Abdulaal, M. R., Haddad, N. M. N., Sun, J. K., & Silva, P. S. (2016) · Seminars in Ophthalmology · doi:10.3109/08820538.2015.1114829 · Cited by 33
Anti-vascular endothelial growth factor indications in ocular disease.
Ştefan, C., Iliescu, D. A., Timaru, C. M., Schmitzer, S., Algerino, D. S., Mehdi, B., & Jalaladin, H.-R. (2015) · PubMed Central · Cited by 33
Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy
Cabrera, A. P., Mankad, R. N., Marek, L., Das, R., Rangasamy, S., Monickaraj, F., & Das, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082712 · Cited by 34
A Review of Aflibercept Treatment for Macular Disease
Anguita, R., Tasiopoulou, A., Shahid, S. M., Roth, J., Sim, S. Y., & Patel, P. J. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00354-1 · Cited by 38
Subconjunctivally Implanted Hydrogels for Sustained Insulin Release to Reduce Retinal Cell Apoptosis in Diabetic Rats
Imai, H., Misra, G. P., Wu, L., Janagam, D. R., Gardner, T. W., & Lowe, T. L. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16998 · Cited by 33
The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF
Chang, C.-K., Cheng, C.-K., & Peng, C.-H. (2017) · Eye · doi:10.1038/eye.2016.317 · Cited by 32
Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy
Marahrens, L., Kern, R., Ziemssen, T., Fritsche, A., Martus, P., Ziemssen, F., & Roeck, D. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0526-z · Cited by 32
A Novel Machine Learning Algorithm to Automatically Predict Visual Outcomes in Intravitreal Ranibizumab-Treated Patients with Diabetic Macular Edema
Chen, S.-C., Chiu, H., Chen, C., Woung, L., & Lo, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120475 · Cited by 32
Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema
Tayyab, H., Chaudhry, N., & Sadiq, M. A. A. (2019) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.36.2.1194 · Cited by 32
The Role of Angiopoietins in Neovascular Diabetes-Related Retinal Diseases
Collazos-Alemán, J. D., Gnecco-González, S., Jaramillo-Zarama, B., Jiménez-Mora, M. A., & Mendivil, C. O. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01326-9 · Cited by 32
Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy
Dhoot, D. S., & Avery, R. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0825-4 · Cited by 31
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
Karst, S. G., Lammer, J., Mitsch, C., Schober, M., Mehta, J., Scholda, C. D., Kundi, M., Kriechbaum, K., & Schmidt-Erfurth, U. M. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3828-1 · Cited by 31
RELATIONSHIP BETWEEN STAGES OF DIABETIC RETINOPATHY AND LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN AQUEOUS HUMOR AND SERUM
Uzel, A. G. T., Uğurlu, N., Toklu, Y., Çiçek, M., Boral, B., Şener, B., & Çağıl, N. (2018) · Retina · doi:10.1097/iae.0000000000002355 · Cited by 31
Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components
Romano, M. R., Allegrini, D., Guardia, C. D., Schiemer, S., Baronissi, I., Ferrara, M., & Cennamo, G. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-4173-8 · Cited by 31
Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema
Nozaki, M., Kato, A., Yasukawa, T., Suzuki, K., Yoshida, M., & Ogura, Y. (2019) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-019-00662-x · Cited by 31
Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema
Inagaki, K., Hamada, M., & Ohkoshi, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-44130-5 · Cited by 31
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
Hirano, T., Toriyama, Y., Takamura, Y., Sugimoto, M., Nagaoka, T., Sugiura, Y., Okamoto, F., Saito, M., Noda, K., Yoshida, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83811-y · Cited by 31
Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology
Nakao, S., Kusuhara, S., & Murakami, T. (2024) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-024-06558-y · Cited by 30
Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group
Arévalo, J. F., Lasave, A. F., Wu, L., Acón, D., Farah, M. E., Gallego‐Pinazo, R., Alezzandrini, A., Fortuna, V., Quiroz–Mercado, H., Salcedo-Villanueva, G., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307950 · Cited by 31
RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS
Ciulla, T. A., Hussain, R. M., Ciulla, L. M., Sink, B., & Harris, A. (2015) · Retina · doi:10.1097/iae.0000000000000876 · Cited by 30
Subthreshold Photocoagulation Using Endpoint Management in the PASCAL® System for Diffuse Diabetic Macular Edema
Hamada, M., Ohkoshi, K., Inagaki, K., Ebihara, N., & Murakami, A. (2018) · Journal of Ophthalmology · doi:10.1155/2018/7465794 · Cited by 30
Indocyanine Green Angiography-Guided Focal Laser Photocoagulation for Diabetic Macular Edema
Ogura, S., Yasukawa, T., Kato, A., Kuwayama, S., Hamada, S., Hirano, Y., Uemura, A., Yoshida, M., & Ogura, Y. (2015) · Ophthalmologica · doi:10.1159/000437360 · Cited by 30
Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States
Varma, R., Bressler, N. M., Doan, Q. V., Danese, M. D., Dolan, C., Lee, A. P., & Turpcu, A. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.12.007 · Cited by 30
Self-citation
The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema
Lim, S. W., Bandala‐Sanchez, E., Kolic, M., Rogers, S., McAuley, A. K., Lim, L. L., & Wickremasinghe, S. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23325 · Cited by 30
Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting
Elaraoud, I., Andreatta, W., Kidess, A., Bhatnagar, A., Tsaloumas, M. D., Quhill, F., & Yang, Y. C. (2016) · BMC Ophthalmology · doi:10.1186/s12886-015-0178-9 · Cited by 29
Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
Régnier, S. A., Malcolm, W., Haig, J., & Xue, W. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s82556 · Cited by 29
Update of Intravitreal Steroids for the Treatment of Diabetic Macular Edema
Bandello, F. M., Preziosa, C., Querques, G., & Lattanzio, R. (2014) · Ophthalmic Research · doi:10.1159/000362764 · Cited by 29
Visualization of Changes in the Choriocapillaris, Choroidal Vessels, and Retinal Morphology After Focal Laser Photocoagulation Using OCT Angiography
Cole, E. D., Novais, E. A., Louzada, R. N., Moult, E. M., Lee, B., Witkin, A. J., Waheed, N. K., Duker, J. S., & Baumal, C. R. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18473 · Cited by 29
AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA
Bahrami, B., Hong, T., Schlub, T. E., & Chang, A. (2018) · Retina · doi:10.1097/iae.0000000000002253 · Cited by 29
Aqueous Humor Cytokines and Long-Term Response to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema
Felfeli, T., Juncal, V. R., Hillier, R. J., Mak, M. Y. K., Wong, D. T., Berger, A. R., Kohly, R. P., Kertes, P. J., Eng, K. T., Boyd, S. R., et al. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.04.002 · Cited by 29
Effectiveness of artificial intelligence screening in preventing vision loss from diabetes: a policy model
Channa, R., Wolf, R. M., Abràmoff, M. D., & Lehmann, H. P. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00785-z · Cited by 32
Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials
Chen, G., Li, W., Tzekov, R. T., Jiang, F., Mao, S., & Tong, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115797 · Cited by 29
Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone
Cáceres‐del‐Carpio, J., Costa, R. D., Haider, A. A., Narayanan, R., & Kuppermann, B. D. (2015) · Developments in ophthalmology · doi:10.1159/000431198 · Cited by 29
Assessment of the Real-Life Usage of Intravitreal Dexamethasone Implant in the Treatment of Chronic Diabetic Macular Edema in France
Querques, G., Darvizeh, F., Querques, L., Capuano, V., Bandello, F. M., & Souied, E. H. (2016) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2016.0010 · Cited by 29
Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
Mira, F. S., Paulo, M., Henriques, F., & Figueira, J. (2017) · Journal of Ophthalmology · doi:10.1155/2017/5632634 · Cited by 29
Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema
Hutton, D. W., Glassman, A. R., Liu, D., Sun, J. K., DRCR Retina Network, Sneath, M., Chen, M., Jelemensky, P. A., Miller, R., Basham, S. R., et al. (2023) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.6142 · Cited by 30
Self-citation
Current and investigational drugs for the treatment of diabetic retinopathy
Tolentino, M. S., Tolentino, A. J., & Tolentino, M. J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1201062 · Cited by 28

Authors: Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W.
Affiliations: Elman Retina Group (US)
Jaeb Center for Health Research (US)
Johns Hopkins University (US)
Charlotte Eye Ear Nose & Throat Associates (US)
Northwestern University (US)
Retina Associates of Kentucky (US)
Corresponding author: Ayala, Allison
ORCID: Elman, Michael J.
Ayala, Allison
Bressler, Neil M.
Browning, David
Flaxel, Christina J.
Glassman, Adam R.
Jampol, Lee M.
Venue: Ophthalmology
Publisher: Elsevier BV
Published: 2015-02
Volume: 122
Issue: 2
Pages: 375-381
ISSN: 0161-6420 (ISSN-L)
DOI: 10.1016/j.ophtha.2014.08.047
PMC: PMC4520307
OpenAlex: W1980342089
Cited by: 562
References: 10
Citations by year: 2026: 8 · 2025: 18 · 2024: 22 · 2023: 20 · 2022: 35 · 2021: 39 · 2020: 55 · 2019: 41 · 2018: 45 · 2017: 79 · 2016: 72 · 2015: 73
FWCI: 79.09
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Ophthalmology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Eye Institute (EY14231, EY-14229, EY18817, EY023207, U10EY018817, U10EY014229, U10EY023207, U10EY014231, UG1EY014231)
Topics: Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords: diabetic macular edema, ranibizumab, intravitreal injection, best-corrected visual acuity, long-term visual outcomes, anti-VEGF therapy, vision loss, treatment duration extension, retinal laser treatment, anti-angiogenic therapy, treatment burden reduction
MeSH terms: Ranibizumab, Aged, Combined Modality Therapy, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Visual Acuity, Treatment Outcome, Laser Coagulation, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks